Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
31
1
2019
Statut:
ppublish
Résumé
The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established. Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up. In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients). Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
The prognostic value of pretreatment systemic immune-inflammation index (SII) in lung cancer has yet to be fully established.
METHODS
METHODS
Relevant articles were obtained by performing a systematic search. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were used to assess the relationship between SII index and overall survival (OS) in lung cancer; the OS was calculated from the time of cancer diagnosis to the date of death due to any cause or to the last date of follow-up.
RESULTS
RESULTS
In total, 2786 patients with lung cancer from 7 studies were included in this meta-analysis. The median thresholds to define high SII was 640 (range 395.4-1600) in the analyzed studies. The pooled HR for OS was 1.77 (95% CI: 1.54-2.00, P < .001), suggesting that the patients with a high SII score had a worse OS. In addition, results from subgroup meta-analysis showed the significant prognostic significance of SII in lung cancer. Especially, the predictive value of SII was significant in the multivariable model for NSCLC (HR: 1.97, 95% CI: 1.69-2.25, P < .001; 5 studies, 1746 patients), and SCLC (HR: 1.38, 95% CI: 1.02-1.85, P < .001; 1 study, 919 patients).
CONCLUSION
CONCLUSIONS
Our data suggest that high SII index indicates poor survival rate in lung cancer. Further researches are warranted to verify the significance of SII index in clinical practice.
Identifiants
pubmed: 30653090
doi: 10.1097/MD.0000000000013788
pii: 00005792-201901180-00005
pmc: PMC6370019
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13788Références
World J Oncol. 2018 Feb;9(1):13-20
pubmed: 29581811
Br J Pharmacol. 2018 Aug;175(15):3100-3110
pubmed: 29777586
Tohoku J Exp Med. 2015;236(4):297-304
pubmed: 26250537
J Transl Med. 2017 Oct 31;15(1):221
pubmed: 29089030
Adv Clin Exp Med. 2018 Sep;27(9):1317-1323
pubmed: 29790694
Prostate. 2018 Mar;78(4):250-256
pubmed: 29285775
Steroids. 2018 May;133:96-101
pubmed: 29155217
J Thorac Dis. 2011 Jun;3(2):122-33
pubmed: 22263075
Future Oncol. 2018 Oct;14(25):2643-2650
pubmed: 29747545
J Thorac Oncol. 2008 Aug;3(8):917-28
pubmed: 18670313
Cell Physiol Biochem. 2018;46(4):1595-1605
pubmed: 29694985
Oncotarget. 2017 Jun 29;8(43):75381-75388
pubmed: 29088873
Chin J Cancer. 2017 Sep 12;36(1):75
pubmed: 28899420
Thorac Cancer. 2018 Jan;9(1):112-119
pubmed: 29105365
Cell Mol Life Sci. 2017 Oct;74(19):3491-3507
pubmed: 28488110
Br J Cancer. 2018 Mar 20;118(6):761-762
pubmed: 29485981
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Cancer Invest. 2016 Sep 13;34(8):378-84
pubmed: 27558529
Cancer Immunol Res. 2018 Apr;6(4):372-377
pubmed: 29610422
Future Oncol. 2017 Jul;13(16):1405-1414
pubmed: 28685599
Clin Cancer Res. 2014 Dec 1;20(23):6212-22
pubmed: 25271081
In Vivo. 2018 May-Jun;32(3):663-667
pubmed: 29695576
Cancer Causes Control. 2018 Jun;29(6):581-588
pubmed: 29663110
Adv Exp Med Biol. 2016;893:1-19
pubmed: 26667336
Lung Cancer. 2015 May;88(2):215-22
pubmed: 25748103
Clin Chim Acta. 2018 Sep;484:272-277
pubmed: 29860033
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Lung. 2017 Apr;195(2):217-224
pubmed: 28154994
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878